IRVINGTON, NY--(Marketwire - August 04, 2008) - Electro-Optical Sciences, Inc. ("EOS") (NASDAQ: MELA) today announced that patient accrual in the MelaFind® pivotal trial was completed last week. MelaFind is a non-invasive, point-of-care instrument designed and developed by EOS to assist in the early diagnosis of melanoma, the deadliest form of skin cancer.
